Table 1. Baseline characteristics of HCC patients.
| Category | Median (range)/N (%) |
|---|---|
| Gender (male/female) | 337 (88.0%)/46 (12.0%) |
| Age, years | 50 (41, 59) |
| Smoke (yes/no) | 128 (33.4%)/255 (66.6%) |
| Drink (yes/no) | 76 (19.8%)/307 (80.2%) |
| Diabetes (yes/no) | 34 (8.9%)/349 (91.1%) |
| Cirrhosis (yes/no) | 253 (66.1%)/130 (33.9%) |
| Ascites (yes/no) | 45 (11.7%)/338 (88.3%) |
| Tumor diameter, cm | 4.3 (3.0, 7.3) |
| Tumor number (multiple/single) | 113 (29.5%)/270 (70.5%) |
| Vascular invasion (yes/no) | 138 (36.0%)/245 (64.0%) |
| Child-Pugh grade (B/A) | 25 (6.5%)/358 (93.5%) |
| MELD score | 5 (3, 7) |
| BCLC stage (B-C/0~A) | 209 (54.6%)/174 (45.4%) |
| Pathological differentiation (poor-moderate/well) | 315 (82.2%)/68 (17.8%) |
| AFP, ng/mL (>400/≤400) | 123 (32.1%)/260 (67.9%) |
| HBV-DNA, copies/mL (>1,000/≤1,000) | 181 (47.3%)/202 (52.7%) |
| Fibrinogen, g/mL | 3.02 (2.49, 3.65) |
| NLR | 1.90 (1.45, 2.70) |
| dNLR | 1.49 (1.08, 2.15) |
| PLR | 99.49 (71.66, 135.20) |
| LMR | 3.92 (2.83, 5.04) |
| GPR | 0.35 (0.21, 0.71) |
| SII | 316.80 (187.83, 490.00) |
| PNI | 48,90 (45.35, 52.40) |
| APRI | 0.23 (0.15, 0.35) |
| ANRI | 11.91 (8.26, 17.89) |
| ALRI | 23.50 (17.88, 31.68) |
| ALBI | −2.68 (−2.90, −2.43) |
| FIB-4 | 1.76 (1.19, 3.12) |
| S-index | 0.21 (0.13, 0.46) |
| Recurrence (no/early/late) | 154 (40.2%)/198 (51.7%)/31 (8.1%) |
MELD, Model for End-stage Liver Disease; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; HBV, hepatitis B virus; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; GPR, gamma-glutamyl transpeptidase-to-platelet ratio; SII, systemic immune-inflammation index; PNI, prognostic nutritional index; APRI, aspartate transaminase-to-platelet count ratio index; ANRI, aspartate transaminase-to-neutrophil ratio index; ALRI, aspartate transaminase-to-lymphocyte ratio index; ALBI, albumin-bilirubin; FIB-4, fibrosis index based on the four factors.